Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Mizuho Reiterates Neutral on ACADIA Pharmaceuticals, Maintains $19 Price Target

Mizuho Reiterates Neutral on ACADIA Pharmaceuticals, Maintains $19 Price Target

Mizuho analyst Uy Ear reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and maintains $19 price target.

byBenzinga Newsdesk

March 13, 2023

1 minute read

Mizuho analyst Uy Ear reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and maintains $19 price target.

Analyst Ratings

Analyst Ratings for Eastman Chemical

By Benzinga Insights

July 29, 11:36 AM

Within the last quarter, Eastman Chemical (NYSE:EMN) has observed the following analyst ratings:

EMN

News

Meta CEO Mark Zuckerberg Says Apple’s App Store Is A ‘Conflict Of Interest’; Says Only Apple Tries To Limit Apps That Enter Its Store

By Benzinga Newsdesk

November 30, 3:14 PM

- Conference Cal

AAPL

News
Tech

JP Morgan Taps Cleareye.ai To Resolve Trade Finance Challenges

By Anusuya Lahiri

June 20, 8:38 AM

JP Morgan Chase & Co (NYSE: JPM) forged a strategic alliance with Cleareye.ai.

JPM

Curaleaf Violated Labor Law By Refusing To Bargain With Union, NLRB Rules, After String Of Unfortunate Events

By Vuk Zdinjak

December 8, 12:54 PM

The National Labor Relations Board ruled on November 6th that Curaleaf Holdings Inc. (OTCQX: CURLF) (CSE: CURA) violated US labor law by refusing to bargain with unionized workers at its Chicago location, reported

CSE:CURA

Mizuho Reiterates Neutral on ACADIA Pharmaceuticals, Maintains $19 Price Target

Related Posts

Analyst Ratings for Eastman Chemical

Meta CEO Mark Zuckerberg Says Apple’s App Store Is A ‘Conflict Of Interest’; Says Only Apple Tries To Limit Apps That Enter Its Store

JP Morgan Taps Cleareye.ai To Resolve Trade Finance Challenges

Curaleaf Violated Labor Law By Refusing To Bargain With Union, NLRB Rules, After String Of Unfortunate Events